Wall Street sees bigger upside in VKTX, with Koyfin’s average target implying 120% upside versus 99% for BCRX.

Quick ReadJim Cramer predicts a biotech takeover flood, with Lilly posting $19.8B Q1 revenue and Gilead closing a $7.8B ...

This story first appeared in Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here to ...

Biotech companies are spending billions to perfect chemical formulas, only to be tripped up by the one variable they forgot ...

Biotech is now the deepest pocket of leadership in the entire Nasdaq. Everyone can see biotech is moving, and the why is ...

Driven by looming patent cliffs, newly buoyant public markets, and Big Pharma's race to beef up their pipelines, dealmaking in 2026 is off to a strong start.

Biotech stocks are considered extremely high-risk, high-reward investments. Many biotech companies are developing one or more ...

United Therapeutics, a biotechnology company with co-headquarters and manufacturing facilities in Research Triangle Park, has acquired a Boston-area biotech company to boost its efforts in ...

As Greater Boston’s biotech industry sheds jobs, three unlikely regions are showing promise as up-and-coming hubs.

In 2023, ReNAgade Therapeutics launched with $300 million to exploit an “all in one” technology solution for RNA-based therapies. That same year, Tome Biosciences emerged from stealth with $213 ...

Sofinnova Investments’ Jim Healy says biotech innovation is thriving but is skeptical about artificial intelligence’s ability ...

Parabilis Medicines, NewLimit, Enliven Therapeutics, and Kardigan bagged the biggest biotech funding rounds overall in June 2026.